Spect

Spect, previously EyeLogic, operates out of Palo Alto, CA with a fully remote team of seven. As a participant in the Y-Combinator S17 batch, Spect has positioned itself in the healthcare industry, specifically within the Consumer Health and Wellness sub-industry. The company focuses on preventing blindness through value-based retinal screenings that are crucial for the 415 million diabetic patients worldwide at risk of conditions like Diabetic Retinopathy and Glaucoma. Spect utilizes a portable retinal camera that enables screenings to be conducted anywhere by existing medical staff. This innovation is part of a vertically integrated platform designed to streamline the conventional retinal exam process. The platform includes a human-in-the-loop assisted telemedicine system, ensuring high-quality, gradable images and quick dilated exams. Spect guarantees a report turnaround time of less than 24 hours, with all images graded by board-certified ophthalmologists. Their screenings cover various eye diseases, including different stages of macular degeneration. The clinical ecosystem of Spect is built with stringent data privacy and security measures, adhering to FDA regulations, SOC 2 Type 1 Certification, and HIPAA Compliance, while also integrating seamlessly with EMR and EHR systems. The company offers a comprehensive solution that includes a frictionless clinical workflow, rapid exams, and virtual training for medical staff. Spect has expanded its services across the United States, catering to a diverse range of healthcare sectors such as Direct Primary Care, Independent Physician Associations, and Senior Care, among others.